Ma Xuan, Zhu Xuean, Zou Mingli, Zhang Jingjing, Huang Lili, Jiang Shasha, Zhi Yanan
Department of Respiratory Medicine, Suzhou BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University Suzhou 215010, Jiangsu, China.
Department of General Surgery, Pingluo County People's Hospital Shizuishan 753000, Ningxia Hui Autonomous Region, China.
Am J Cancer Res. 2024 Jun 15;14(6):2934-2945. doi: 10.62347/LJDQ3897. eCollection 2024.
To determine the expression of chemokine 8 (CXCL8) in non-small cell lung cancer (NSCLC) patients and analyze its correlation with tumor characteristics and patient prognosis. We conducted a retrospective analysis of 149 NSCLC patients treated between January 2016 and April 2018, measuring serum CXCL8 expression upon admission or prior to treatment. The clinical characteristics, including lymph node metastasis and staging, based on CXCL8 expression levels, were analyzed. Receiver Operating Characteristic (ROC) curves was drawn to assess its predictive value for lymph node metastasis and staging in NSCLC patients. Furthermore, the Kaplan-Meier curve was plotted to assess the impact of CXCL8 on 5-year survival in NSCLC Patients. NSCLC patients exhibited significantly higher serum CXCL8 levels than those with benign tumors (P<0.001), with the high CXCL8 expression group showing a higher incidence of lymph node metastasis or stage III NSCLC (P<0.01). CXCL8 was identified as an independent predictor of lymph node metastasis (AUC=0.730) and higher TNM stage (AUC=0.708), as well as a validated biomarker for predicting five-year survival in NSCLC patients. This study highlights the strong association between CXCL8 expression in NSCLC and patient prognosis, particularly regarding lymph node metastasis and clinical staging, suggesting the need for further research to explore CXCL8's specific role in the tumor microenvironment and its impact on different NSCLC subtypes.
为了确定趋化因子8（CXCL8）在非小细胞肺癌（NSCLC）患者中的表达，并分析其与肿瘤特征及患者预后的相关性。我们对2016年1月至2018年4月期间接受治疗的149例NSCLC患者进行了回顾性分析，测定入院时或治疗前血清CXCL8的表达水平。基于CXCL8表达水平分析包括淋巴结转移和分期在内的临床特征。绘制受试者工作特征（ROC）曲线以评估其对NSCLC患者淋巴结转移和分期的预测价值。此外，绘制Kaplan-Meier曲线以评估CXCL8对NSCLC患者5年生存率的影响。NSCLC患者血清CXCL8水平显著高于良性肿瘤患者（P<0.001），CXCL8高表达组淋巴结转移或III期NSCLC的发生率更高（P<0.01）。CXCL8被确定为淋巴结转移（AUC=0.730）和更高TNM分期（AUC=0.708）的独立预测因子，也是预测NSCLC患者5年生存率的有效生物标志物。本研究强调了NSCLC中CXCL8表达与患者预后之间的密切关联，特别是在淋巴结转移和临床分期方面，表明需要进一步研究以探索CXCL8在肿瘤微环境中的具体作用及其对不同NSCLC亚型的影响。
